Literature DB >> 8501141

Prospective use of bisphosphonates in osteoporosis.

H Fleisch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501141     DOI: 10.1210/jcem.76.6.8501141

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  4 in total

1.  Changes in bone mineral density in patients with Paget's disease treated with risedronate.

Authors:  S Patel; D Pearson; A Bhallah; W Maslanka; D A White; D J Hosking
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

Review 2.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

3.  Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

Authors:  F Falcini; S Trapani; M Ermini; M L Brandi
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

4.  Human farnesyl pyrophosphate synthase inhibition by nitrogen bisphosphonates: a 3D-QSAR study.

Authors:  David Fernández; Joaquín Ortega-Castro; Juan Frau
Journal:  J Comput Aided Mol Des       Date:  2013-08-24       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.